Text size A - A+

Frequently Asked Questions

This acquisition is a significant strategic step for Bausch + Lomb, and it strengthens our pharmaceutical business’s ability to deliver even more meaningful advances to the many physicians and patients we serve.

ISTA’s unique scientific, formulation and medical expertise will benefit our overall portfolio.   The addition of ISTA’s four prescription products - non-steroidal BROMDAY™ for post cataract surgery inflammation and pain; BEPREVE® for ocular allergy; ISTALOL® for intra-ocular pressure; and VITRASE®, a leading spreading agent, strengthens our U.S. product portfolio and provides customers with a more complete offering. These products complement Bausch + Lomb’s branded, generic and OTC eye health products, includingLotemax® for ocular inflammation; Besivance® for the treatment of bacterial conjunctivitis; and branded eye vitamins PreserVision® and Ocuvite®. In addition, we expect our larger combined pipeline of promising late-stage pharmaceutical products to position Bausch + Lomb to succeed for many years to come.

The addition of ISTA’s pipeline nearly doubles the number of mid- to late-stage innovations that were in Bausch + Lomb’s standalone pipeline. ISTA’s pipeline includes candidates in various stages of development to treat ocular conditions including allergy, inflammation and pain, such as PROLENSA™, BEPOMAX™, BEPOSONE™ and T-PRED™. Bausch + Lomb’s pipeline of pharmaceutical innovations includes Mapracorat, the first of a new class of ocular anti-inflammatory agents, and the compound BOL-303259-X, a promising approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.

Finally, ISTA’s strong customer relationships, passion for innovation and focus on delivering therapies that will help patients see better and live better complement Bausch + Lomb’s patient-centered approach to service and innovation.

ISTA is a rapidly growing commercial-stage, multi-specialty pharmaceutical company developing, marketing and selling its own products in the U.S. and Puerto Rico.

The company was formed in 1992 as Advanced Corneal Systems. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. and the company went public in August of that year and was listed on the NASDAQ Global Market. 

The name ISTA came from the Lakota word “IST” for eye. Lakota is a Siouan language spoken by the Lakota people of the Sioux Native American Indian tribes primarily in North Dakota and South Dakota, U.S.

Prior to closing, ISTA employed approximately 330 people in the U.S. in a wide range of functions, with the vast majority in field sales. Bausch + Lomb has roughly 11,000 employees worldwide with approximately 3,800 people in its global Pharmaceuticals business.

Our product portfolio now includes ISTA’s industry-proven non-steroidal BROMDAY™;BEPREVE® for ocular allergy; ISTALOL® for intra-ocular pressure; and VITRASE®, a leading spreading agent. ISTA’s products complement Bausch + Lomb’s branded, generic and OTC eye health products, including Lotemax® for ocular information; Besivance® for the treatment of bacterial conjunctivitis; and branded eye vitamins PreserVision® and Ocuvite®.

Also, the addition of ISTA’s pipeline nearly doubles the number of mid- to late-stage pharmaceutical innovations in Bausch + Lomb’s pipeline. ISTA’s pipeline includes candidates in various stages of development to treat ocular conditions including allergy, inflammation and pain, such as PROLENSA™, T-PRED™, BEPOMAX™ and BEPOSONE™. Bausch + Lomb’s pipeline of pharmaceutical innovations includes Mapracorat, the first of a new class of ocular anti-inflammatory agents to come along in decades, and the compound BOL-303259-X, a promising approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.

Bausch + Lomb combined with ISTA in an all-cash transaction valued at approximately $500 million.  The acquisition will add more than $150 million to Bausch + Lomb’s annualized sales in the U.S. and will be accretive to EBITDA this year.

At this time, there are no planned changes to our products or brands. The integration team will determine if any changes regarding brands or products are necessary in the future.

We will take every possible step to ensure a smooth transition for our customers. This effort should be helped by our overlapping customer base, complementary product portfolio, and manufacturing synergies.

While Bausch + Lomb’s global headquarters is in Rochester, NY, the global Pharmaceutical business will remain headquartered in Madison, NJ.  We are also committed to maintaining a presence in Orange County, CA.

Please continue to rely on the same people, processes and procedures for ordering product or samples for information you might typically need to receive or provide or any other need related to our company, products or services.

We will keep you informed of any changes that may impact you in any way. If you have additional questions, please contact Bausch + Lomb customer service at 1-800-828-9030 (eye care professionals) or 1-800-553-5340 (consumers).